Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2996289

CC(C)C(=O)Nc1ccc(Cl)c(NC2=NC(=O)/C(=C/c3ccc4nccc(N5CCOCC5)c4c3)S2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.35
RAF1 P04049 4/20 0.35
KDM4E B2RXH2 1/20 0.34
RECQL P46063 1/20 0.34
EGFR P00533 3/20 0.33
FGFR1 P11362 1/20 0.33
KDR P35968 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
PIK3CG P48736 1/20 0.33
PRKDC P78527 1/20 0.33
PIK3C3 Q8NEB9 1/20 0.33
MEN1 O00255 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C19 P33261 2/20 0.32
KMT2A Q03164 2/20 0.32
LMNA P02545 2/20 0.32
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2996297 1.00 BRAF (0.35) BRAFRAF1KDM4ERECQLEGFR
Trifluoroacetic Acid SCHEMBL2990510 0.93 ENPP2 (0.40) KDM4ERECQLEGFRMEN1CYP2D6
Trifluoroacetic Acid SCHEMBL2990505 0.93 ENPP2 (0.40) KDM4ERECQLEGFRMEN1CYP2D6
Trifluoroacetic Acid SCHEMBL4585836 0.89 MEN1 (0.37) BRAFKDM4EEGFRMEN1KMT2A
Trifluoroacetic Acid SCHEMBL4585816 0.89 MEN1 (0.37) BRAFKDM4EEGFRMEN1KMT2A
Trifluoroacetic Acid SCHEMBL2996830 0.88 PIK3CA (0.36) PIK3CDPIK3CAPIK3CBMTORPIK3CG
Trifluoroacetic Acid SCHEMBL2996823 0.88 PIK3CA (0.36) PIK3CDPIK3CAPIK3CBMTORPIK3CG
Trifluoroacetic Acid SCHEMBL2990672 0.85 MAPT (0.43) RECQLMEN1KMT2ALMNAALDH1A1
Trifluoroacetic Acid SCHEMBL5048576 0.85 MAPT (0.43) RECQLMEN1KMT2ALMNAALDH1A1
Trifluoroacetic Acid SCHEMBL2990678 0.84 ALDH1A1 (0.35) BRAFKDM4EMEN1CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214455-A1 Novel Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-04 US claimed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 US disclosed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 EP disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080214455-A1 Novel Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2008-09-04 US disclosed
EP-1879563-A4 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-07-16 EP disclosed
EP-1879563-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-01-23 EP disclosed
WO-2006132739-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214455-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 BRAF 3988/4885RAF1 2699/4885KDM4E 2665/4885
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 BRAF 2915/4885RAF1 4349/4885KDM4E 2784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.